Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.
Saved in:
| Title: | Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness. |
|---|---|
| Authors: | Lopez-Mejia IC; Center for Integrative Genomics, University of Lausanne, Switzerland., Pijuan J; Laboratory of Neurogenetics and Molecular Medicine - Pediatric Institute of Rare Diseases, Institut de Recerca Sant Joan de Déu, Barcelona, Spain., Navaridas R; Departament de Ciències Mèdiques Bàsiques, IRBLleida, University of Lleida, Spain., Santacana M; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain., Gatius S; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain., Velasco A; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain., Castellà G; Biostatistics Unit, Hospital Universitari Arnau de Vilanova, IRB-Lleida, University of Lleida, Spain., Panosa A; Flow Cytometry and Confocal Microscopy Unit, IRBLleida, University of Lleida, Spain., Cabiscol E; Departament de Ciències Mèdiques Bàsiques, IRBLleida, University of Lleida, Spain., Pinyol M; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain., Coll L; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran via de l'Hospitalet, Barcelona, Spain., Bonifaci N; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Peña LP; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran via de l'Hospitalet, Barcelona, Spain., Vidal A; Department of Pathology-Hospital, Universitari de Bellvitge, Barcelona, Spain.; Xenopat S.L., Parc Cientific de Barcelona (PCB), Spain., Villanueva A; Xenopat S.L., Parc Cientific de Barcelona (PCB), Spain.; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, Barcelona, Spain., Gari E; Departament de Ciències Mèdiques Bàsiques, IRBLleida, University of Lleida, Spain., Llobet-Navàs D; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran via de l'Hospitalet, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Fajas L; Center for Integrative Genomics, University of Lausanne, Switzerland., Matias-Guiu X; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran via de l'Hospitalet, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Department of Pathology-Hospital, Universitari de Bellvitge, Barcelona, Spain., Yeramian A; Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova (HUAV), IRBLleida, University of Lleida, Spain. |
| Source: | Molecular oncology [Mol Oncol] 2023 Jan; Vol. 17 (1), pp. 98-118. Date of Electronic Publication: 2022 Dec 07. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.13346 |
